Cure8 research brief
This work focuses on tailoring adalimumab dosing using routine drug-level data, which may help patients on adalimumab achieve target drug concentrations associated with better control of IBD.
It highlights patient factors (weight, albumin) that influence drug levels and shows MIPD performance improves with repeated monitoring.
Patients on adalimumab or other anti-TNF therapies, clinicians who order therapeutic drug monitoring or manage biologic dosing, and researchers working on pharmacometrics or dose-optimization in IBD.
This study developed and validated a population pharmacokinetic (popPK) model for adalimumab using real-world therapeutic drug monitoring (TDM) data from adult IBD patients (201 patients, 709 trough concentrations).
The one-compartment model identified body weight and serum albumin as key predictors of adalimumab clearance and showed good predictive performance across multiple evaluation methods.
The authors used Monte Carlo simulations to estimate probabilities of reaching steady-state trough concentration targets (≥8, ≥10, ≥12 mg·L⁻¹) under different dosing, weight, and albumin scenarios, and found attainment decreased with higher body weight, lower albumin, and stricter targets.
Predictive accuracy improved as more individual TDM data were added, supporting model-informed precision dosing (MIPD) in routine care.
Practical takeaways: the model could help personalize adalimumab dosing—especially for patients with higher clearance risk (higher weight, low albumin)—but this report describes model development and simulations rather than prospective outcome data.
Structured content depth: abstract — the summary and results are drawn from the article abstract on PubMed. This is a model-development and simulation study using retrospective routine TDM data; it does not report prospective clinical outcomes from using the model in practice. External validation or prospective trials would be needed to confirm clinical benefit.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Competing Interests: The authors declare no conflicts of interest. Ethics approval: The study was approved by the Clinical Research Ethics Committee of Autonomous Community of Aragon (CEICA) on 12 June 2024 (registration no. EOM24/034). The procedures established in this research are designed following the principles of good clinical practice and the Declaration of Helsinki. Consent to Participate: Written informed consent allowing the use of clinical data for research purposes was prospectively obtained during routine clinical follow-up at the IBD Unit. Consent for Publication: Not applicable.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
Proactive monitoring of adalimumab levels could help keep drug concentrations therapeutic and reduce loss of response during maintenance therapy for ulcerative colitis.
